ZUG, Switzerland, June 26, 2023 – MoonLake Immunotherapeutics MLTX ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has commenced an underwritten public offering of $250 million of its Class A ordinary shares and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares.